
## Valentina Andreasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4211977/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. Radiologia Medica, 2021, 126, 745-760.	7.7	72
2	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, 270, 422-433.	4.2	53
3	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. European Journal of Surgical Oncology, 2018, 44, 778-783.	1.0	49
4	Update on gastroenteropancreatic neuroendocrine tumors. Digestive and Liver Disease, 2021, 53, 171-182.	0.9	45
5	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Annals of Surgical Oncology, 2020, 27, 1348-1355.	1.5	44
6	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery, 2019, 166, 157-163.	1.9	40
7	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. Hpb, 2020, 22, 1645-1653.	0.3	33
8	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 273-287.	2.5	32
9	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. Hpb, 2018, 20, 197-203.	0.3	29
10	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nuclear Medicine Communications, 2020, 41, 896-905.	1.1	28
11	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. Neuroendocrinology, 2019, 109, 165-170.	2.5	26
12	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	3.3	26
13	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. Hpb, 2020, 22, 1227-1239.	0.3	26
14	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Physica Medica, 2019, 57, 41-46.	0.7	22
15	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	5.9	21
16	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. Diagnostics, 2021, 11, 192.	2.6	20
17	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. American Journal of Surgery, 2020, 220, 284-289.	1.8	19
18	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3928-3936.	1.5	19

VALENTINA ANDREASI

#	Article	IF	CITATIONS
19	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clinical and Translational Imaging, 2019, 7, 181-188.	2.1	18
20	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. American Journal of Surgery, 2021, 222, 513-520.	1.8	16
21	Diagnostic strategy with a solid pancreatic mass. Presse Medicale, 2019, 48, e125-e145.	1.9	15
22	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Digestive and Liver Disease, 2019, 51, 735-740.	0.9	15
23	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. Surgery, 2021, 170, 1215-1222.	1.9	15
24	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	1.6	14
25	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. Hpb, 2020, 22, 1766-1774.	0.3	13
26	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. Neuroendocrinology, 2021, 111, 728-738.	2.5	13
27	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2020, 21, 48.	3.0	13
28	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. Cancers, 2020, 12, 1235.	3.7	12
29	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2019, 8, 1611.	2.4	11
30	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. Endoscopic Ultrasound, 2021, 10, 372.	1.5	11
31	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	3.1	10
32	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers, 2021, 13, 5014.	3.7	9
33	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 139-144.	5.7	7
34	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology, 2019, 19, 57-63.	1.1	6
35	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. Clinical and Translational Imaging, 2019, 7, 363-371.	2.1	4
36	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. Surgery, 2020, 168, 816-824.	1.9	4

VALENTINA ANDREASI

#	Article	IF	CITATIONS
37	Survival after active surveillance <i>versus</i> upfront surgery for incidental small pancreatic neuroendocrine tumours. British Journal of Surgery, 2022, 109, 733-738.	0.3	4
38	Clinical and economic validation of grade B postoperative pancreatic fistula subclassification. Surgery, 2022, 171, 846-853.	1.9	3
39	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	2.4	3
40	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. Updates in Surgery, 2021, , 1.	2.0	2
41	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. Current Oncology Reports, 2022, 24, 227-239.	4.0	2
42	Guideline for the Management of Pancreatic Neuroendocrine Tumor. , 2017, , 161-172.		0
43	New Surgical Strategies. , 2021, , 113-128.		0
44	Non Functional Pancreatic Neuroendocrine Tumors. , 2021, , 125-135.		0